Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)

• Published in: Annals of the rheumatic diseases Vol. 76; no. 1; pp. 203 - 207
• Main Authors: Strand, Vibeke, Mease, Philip, Gossec, Laure, Elkayam, Ori, van den Bosch, Filip, Zuazo, James, Pricop, Luminita, Mpofu, Shephard
• Format: Journal Article
• Language: English
• Published: England Elsevier Limited 01.01.2017; BMJ Publishing Group
• Subjects: Adult; Aged; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic - drug therapy; Clinical outcomes; Drug Administration Schedule; Female; Humans; Immunologic Factors - administration & dosage; Immunologic Factors - therapeutic use; Injections, Intravenous; Injections, Subcutaneous; Life Sciences; Male; Middle Aged; Patient Reported Outcome Measures; Psoriatic arthritis; Quality of Life; Severity of Illness Index; Treatment Outcome; Patient perspective; Treatment; Quality Indicators; Psoriatic Arthritis
• ISSN: 0003-4967; 1468-2060; 1468-2060
• DOI: 10.1136/annrheumdis-2015-209055

ObjectiveTo evaluate the effect of secukinumab on patient-reported outcomes (PROs) in subjects with active psoriatic arthritis (PsA) in the FUTURE 1 study.MethodsSubjects were randomised 1:1:1 to receive intravenous (i.v.) secukinumab 10 mg/kg at weeks 0, 2 and 4 followed by subcutaneous secukinumab 150 or 75 mg every 4 weeks or matching placebo until week 24.ResultsAt week 24, subjects receiving secukinumab i.v.→150 mg or i.v.→75 mg reported greater least squares mean changes from baseline than those receiving placebo in patient global assessment of disease activity (−20.6 and −20.0 vs −7.4, respectively), patient assessment of pain (−20.8 and −20.4 vs −6.7), psoriatic arthritis quality of life (−3.5 and −3.2 vs −0.4), Dermatology Life Quality Index (−8.8 and −7.9 vs 0.7); p<0.0001 vs placebo for both secukinumab groups for above PROs and Functional Assessment of Chronic Illness Therapy-Fatigue (6.74 (p<0.05 vs placebo) and 6.03 vs 4.00); all of which well exceeded minimum clinically important differences.ConclusionsIn subjects with PsA, secukinumab treatment resulted in clinically meaningful improvements in global disease activity, pain, generic and disease-specific measures of health-related quality of life and fatigue.Trial registration numberNCT01392326; Results.